Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | BCL9 | O00512 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.39 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28692684 | 0.84 | LMNA (0.53) | MAPTLMNAKMT2AALDH1A1 | |
| SCHEMBL5827968 | 0.79 | HTR2A (0.80) | HTR2ABCL9CTNNB1GAAALDH1A1 | |
| SCHEMBL7094532 | 0.78 | HTR2A (0.53) | HTR2AMAPTBCL9CTNNB1GAA | |
| SCHEMBL436082 | 0.77 | LMNA (0.51) | MAPTLMNAKMT2AALDH1A1 | |
| SCHEMBL28692686 | 0.77 | LMNA (0.51) | MAPTLMNAKMT2AALDH1A1 | |
| SCHEMBL7096139 | 0.77 | HTR2A (0.52) | HTR2AMAPTBCL9CTNNB1GAA | |
| SCHEMBL120371 | 0.77 | HTR2A (0.49) | HTR2AMAPTGAALMNAKMT2A | |
| SCHEMBL409598 | 0.77 | HTR2A (0.59) | HTR2AMAPTBCL9CTNNB1GAA | |
| SCHEMBL4871308 | 0.76 | LMNA (0.50) | MAPTLMNAKMT2AALDH1A1 | |
| SCHEMBL12524469 | 0.76 | HTR2A (0.74) | HTR2AMAPTBCL9CTNNB1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042820-A1 | Tubulin Binding Anti Cancer Agents And Prodrugs Thereof | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042820-A1 | Tubulin Binding Anti Cancer Agents And Prodrugs Thereof | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20070060534-A1 | Anthracycline analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060534-A1 | Anthracycline analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| EP-1173414-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064864-A9 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2001-12-27 | — | — | WO | disclosed |
| WO-2000064864-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060534-A1 | Anthracycline analogs | TOP2A, TOP2B, TOP1 | HTR2A 4344/4885MAPT 4692/4885BCL9 31/4885 |
| US-20090042820-A1 | Tubulin Binding Anti Cancer Agents And Prodrugs Thereof | TUBB1, TUBB, TUBB6 | HTR2A 4714/4885MAPT 276/4885BCL9 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.